島根の花嫁が花嫁になる:プログルカゴン製ペプチドは,変革的な治療法をもたらします
1MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK.
Cell
|April 8, 2021
まとめ
研究者はプログルカゴンから新しいペプチドを発見し,2型糖尿病の治療に繋がった. これらのペプチドの発見は 代謝障害に対する世界的な健康上の利点をもたらします
科学分野:
- 内分泌学と代謝
- 分子生物学
- 薬理学について
背景:
- プログルカゴン遺伝子は複数のペプチドホルモンをコードする.
- これらのペプチドの生理学的役割を理解することは,代謝疾患の研究にとって極めて重要です.
研究 の 目的:
- 新種のペプチドが 発見されました
- これらの新発見ペプチドの生理学的意義を確立するために.
主な方法:
- 新しいペプチドを特定する 遺伝的配列解析
- ペプチドの機能を決定するための生理学的研究.
- 治療の可能性を評価する臨床研究
主要な成果:
- プログルカゴン配列内のこれまで未知のペプチドの識別
- これらの新しいペプチドの特定の生理学的役割の解明.
- これらのペプチドを治療開発のターゲットとして検証
結論:
- プログルカゴン由来ペプチドの発見は,代謝疾患の研究を大幅に進めた.
- これらの発見は,2型糖尿病および関連疾患に対する効果的な治療法の開発につながりました.
- ドラッカー,ハベナー,ホルストの研究は 患者ケアに世界的な影響を与えた.
関連する概念動画
Glucagon-like Receptor Agonists
538
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
538
Hypoglycemia and Glucagon
511
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
511
Hormones Regulating Blood Glucose
5.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
5.4K
Dipeptidyl Peptidase 4 Inhibitors
327
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
327
Insulin: Biosynthesis, Chemistry, and Preparation
781
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
781
Oral Hypoglycemic Agents: Glinides
372
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
372


